UPB (Upstream Bio) Accounts Payable & Accrued Expense : $7.98 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Accounts Payable & Accrued Expense?

Upstream Bio's quarterly accounts payable & accrued expense declined from Sep. 2024 ($8.08 Mil) to Dec. 2024 ($7.34 Mil) but then increased from Dec. 2024 ($7.34 Mil) to Mar. 2025 ($7.98 Mil).

Upstream Bio's annual accounts payable & accrued expense increased from Dec. 2022 ($3.88 Mil) to Dec. 2023 ($4.30 Mil) and increased from Dec. 2023 ($4.30 Mil) to Dec. 2024 ($7.34 Mil).

Upstream Bio Accounts Payable & Accrued Expense Historical Data

The historical data trend for Upstream Bio's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Accounts Payable & Accrued Expense Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

3.88

4.30

7.34

Upstream Bio Quarterly Data
	Dec22	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial			-	8.63	8.08	7.34	7.98

Upstream Bio Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.